Jeev.Bo

JEEV.BO's capital structure is characterized by a debt-to-equity ratio of 0.41, indicating a relatively conservative leverage position. The company's liquidity is assessed as medium, with a current ratio of 2.38, suggesting it can cover its short-term obligations but with limited excess cash. However, the company's cash and equivalents amount to INR 2.42 million, which is significantly lower than its long-term debt of INR 205.8 million, resulting in a net cash position that is negative after subtracting total debt.

In terms of profitability, JEEV.BO's return on equity (ROE) is 0.27%, and its return on assets (ROA) is 0.17%, both of which are below the industry median for biotechnology and medical research firms. The company's operating income of INR 11.59 million and net income of INR 1.34 million indicate a narrow profit margin, which may limit its ability to reinvest in growth or withstand economic downturns.

JEEV.BO's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks, particularly in the healthcare diagnostics sector, which is subject to regulatory and technological changes.

The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial period. The outlook for the current fiscal year (FY) and the next FY does not indicate a substantial increase in revenue, and the company's capital expenditure of INR 160.31 million suggests a focus on maintaining existing operations rather than expanding into new markets or developing new products.

Risk factors for JEEV.BO include its medium liquidity risk, as highlighted by the negative net cash position after subtracting total debt. The company's dilution potential is assessed as low, with no significant dilution events reported in the latest financial data. However, the company's free cash flow is negative at INR 97.21 million, which may necessitate future financing activities that could lead to dilution.

Recent events for JEEV.BO include the filing of its latest financial statements, which provide a snapshot of its financial health and strategic direction. No significant earnings call transcripts or other recent disclosures have been reported, which may limit the availability of qualitative insights into the company's performance and future plans.